根据抗生素耐药性评估幽门螺杆菌治疗的有效性
这项前瞻性、多中心、国际注册研究分析了西班牙2013至2021年2852例初治和1118例非初治幽门螺杆菌感染成人,按抗生素耐药性评估一线及补救治疗的有效性。初治患者中克拉霉素、甲硝唑和喹诺酮耐药率分别为22%、27%和18%,含铋三合一单胶囊和含铋四联疗法在耐药情况下仍提供最佳治愈率。非初治患者耐药率分别为49%、41%和24%,仅三合一单胶囊和左氧氟沙星三联疗法提供鼓舞性结果。
要点
- 初治患者中克拉霉素、甲硝唑和喹诺酮耐药率分别为22%、27%和18%。
- 初治患者中替硝唑伴同方案根除率99%(90/91)vs 甲硝唑伴同方案84%(90/107)。
- 非初治患者中克拉霉素、甲硝唑和喹诺酮耐药率分别为49%、41%和24%。
核心结论
- 在幽门螺杆菌抗生素耐药率高的地区,初治患者最佳选择为含铋三合一单胶囊、含铋四联疗法和替硝唑伴同方案。
- 非初治患者中,含铋三合一单胶囊和左氧氟沙星三联疗法提供了鼓舞性结果。
研究设计与样本
- 前瞻性、多中心、国际注册研究(欧洲幽门螺杆菌管理注册),纳入2013至2021年西班牙胃肠病学协会-研究电子数据采集系统中所有感染且培养确诊的成人患者。
- 共分析2852例有培养结果的初治患者和1118例非初治患者。
主要发现
- 初治患者中克拉霉素、甲硝唑和喹诺酮耐药率分别为22%、27%和18%;无论耐药与否,含铋三合一单胶囊(91%)和含铋四联疗法最有效。
- 初治患者中替硝唑伴同方案根除率99%(90/91)vs 甲硝唑伴同方案84%(90/107)。
- 初治患者中三联方案、序贯方案或含甲硝唑伴同方案未达到最佳结果。
- 非初治患者中克拉霉素、甲硝唑和喹诺酮耐药率分别为49%、41%和24%;仅含铋三合一单胶囊(87%)和左氧氟沙星三联疗法(85%)提供鼓舞性结果。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Antibiotic resistance is one of the main factors that determine the efficacy of treatments to eradicate Helicobacter pylori infection. Our aim was to evaluate the effectiveness of first-line and rescue treatments against H. pylori in Europe according to antibiotics resistance. METHODS: Prospective, multicenter, international registry on the management of H. pylori (European Registry on H. pylori Management). All infected and culture-diagnosed adult patients registered in the Spanish Association of Gastroenterology-Research Electronic Data Capture from 2013 to 2021 were included. RESULTS: A total of 2,852 naive patients with culture results were analyzed. Resistance to clarithromycin, metronidazole, and quinolones was 22%, 27%, and 18%, respectively. The most effective treatment, regardless of resistance, were the 3-in-1 single capsule with bismuth, metronidazole, and tetracycline (91%) and the quadruple with bismuth, offering optimal cure rates even in the presence of bacterial resistance to clarithromycin or metronidazole. The concomitant regimen with tinidazole achieved an eradication rate of 99% (90/91) vs 84% (90/107) with metronidazole. Triple schedules, sequential, or concomitant regimen with metronidazole did not achieve optimal results. A total of 1,118 non-naive patients were analyzed. Resistance to clarithromycin, metronidazole, and quinolones was 49%, 41%, and 24%, respectively. The 3-in-1 single capsule (87%) and the triple therapy with levofloxacin (85%) were the only ones that provided encouraging results. DISCUSSION: In regions where the antibiotic resistance rate of H. pylori is high, eradication treatment with the 3-in-1 single capsule, the quadruple with bismuth, and concomitant with tinidazole are the best options in naive patients. In non-naive patients, the 3-in-1 single capsule and the triple therapy with levofloxacin provided encouraging results.
引用
- Bujanda L, Nyssen OP, Ramos J, et al. Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance. Am J Gastroenterol. 2023. PMID: 37983769. doi:10.14309/ajg.0000000000002600
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。